Abstract: Presbycusis is a significant public health issue faced by aging societies, with its pathogenesis involving complex interactions among chronic low-grade inflammation, oxidative stress, and metabolic dysregulation. Chronic low-grade inflammation is one of the core features of inflammatory aging, characterized by a persistent low-level inflammatory state without an obvious source of infection, accompanied by elevated pro-inflammatory factors (such as interleukin-6, tumor necrosis factor-α, and interleukin-1β) and decreased anti-inflammatory factors (such as interleukin-10). Recent studies have shown a close relationship between the pathological processes of presbycusis and chronic low-grade inflammation, with anti-inflammatory therapeutic strategies, including mammalian target of rapamycin inhibitors, nanodrug delivery systems, and gene editing technologies, demonstrating potential therapeutic value. This paper reviews the latest research on the molecular mechanisms, clinical associations, and therapeutic strategies related to inflammatory pathways in presbycusis, and suggests future research prospects that combine multi-omics technologies with targeted delivery systems to achieve precise clinical interventions.

Key words: presbycusis, inflammaging, inflammation balance, anti-inflammatory therapy